Amgen Inc

Stock Symbol: AMGN

One Amgen Centre Drive
Thousand Oaks, CA 91320
805-447-1000 (phone)
805-447-1010 (fax)

Website: Amgen

Industry: Biotechnology & Drugs

Index Membership: S&P 100; S&P 500; S&P 1500 Super Comp; Nasdaq 100

Amgen Inc Description:
Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

Amgen Inc Financial Summary:
Oct. 24, 2007--Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.08 for the third quarter of 2007, an increase of 4 percent compared to $1.04 for the third quarter of 2006. Adjusted net income, excluding stock option expense and certain other expenses, decreased 4 percent to $1,181 million in the third quarter of 2007 compared to $1,224 million in the third quarter of 2006. Stock option expense on a per share basis totaled 2 cents and 3 cents for the third quarter of 2007 and 2006, respectively. Total revenue remained unchanged during the third quarter of 2007 at $3.6 billion versus the third quarter of 2006.

Amgen Inc Business Summary:
Amgen Inc., a biotechnology company, that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation, and oncology worldwide. The company's principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis; Vectibix, which binds specifically to the human epidermal growth factor receptor and interferes with signals that stimulate growth and survival of the cancer cell; and Sensipar for treating chronic kidney disease patients on dialysis. Amgen has a joint venture with Kirin Brewery Company, Limited, for the development and commercialization of products based on advanced biotechnology, as well as a co-promotion agreement with Wyeth related to the manufacture, supply, inventory, and allocation of bulk supplies of ENBREL. The company also entered into a collaboration agreement with Cytokinetics, Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. Amgen, Inc. was founded in 1980 and is based in Thousand Oaks, California.